Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
BURLINGTON, Mass., Feb. 18, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets 2016 Global Healthcare Conference on Tuesday, February 23, 2016 at 8:30 a.m. Eastern Time at the New York Palace Hotel in New York City.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections for knee OA annually. The company is also investigating another product candidate, FX007, a locally administered TrkA receptor antagonist for post-operative pain.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T : 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
